1.Product Name:SCYLLO-INOSITOL
CAS: 488-59-5
MF: C6H12O6
MW: 180.16
SCYLLO-INOSITOL Chemical Properties
Melting point :350 °C
Boiling point 291.3±40.0 °C(Predicted)
|
Appearance |
White or off white powder |
|
Identification HPLC |
The retention time of the liquid phase in the content determination item is consistent with that of the standard product |
|
Water, % ≤ |
≤0.5% |
|
Limit of lead, , mg/kg ≤ |
≤0.5%( mg/kg) |
|
Assay(on the basis of no water) |
≥98.0% |
2.Bioactivities and Mechanisms of Action
2.1 Blood Glucose Regulation and Insulin Sensitization
Improves insulin resistance: Activates AMPK signaling pathway, enhancing GLUT4 membrane translocation in skeletal muscle and adipocytes. Preclinical studies show 20%-30% reduction in fasting blood glucose in type 2 diabetic models.
Suppresses gluconeogenesis: Downregulates hepatic phosphoenolpyruvate carboxykinase (PEPCK) expression, reducing hepatic glucose output with synergistic effects to conventional hypoglycemic agents (e.g., metformin).
2.2 Neuroprotective Functions
Anti-amyloid β toxicity: Specifically binds Aβ42 oligomers, inhibiting fibrillar deposition. Alzheimer’s transgenic model studies demonstrate >40% reduction in brain amyloid plaques at 100 mg/kg/day oral dose.
Promotes neuronal survival: Upregulates brain-derived neurotrophic factor (BDNF) expression, protecting hippocampal neurons from oxidative stress and potentially mitigating cognitive decline.
2.3 Cardiovascular Health Maintenance
Endothelial function optimization: Increases nitric oxide (NO) synthase activity, improving vasodilation and reducing arterial stiffness.
Lipid metabolism regulation: Inhibits HMG-CoA reductase, lowering serum total cholesterol (TC) and LDL levels (15%-18% TC reduction in animal studies).
Scyllo-Inositol (488-59-5) has emerged as a core functional factor in neuroprotective and metabolic health nutraceuticals, leveraging its multi-target bioactivities and superior brain bioavailability. Implementation of 2024 excipient regulations and microencapsulation advances will shift applications toward precision formulations and intelligent delivery systems. Critical future breakthroughs include: ① Cost-reducing green manufacturing; ② Large-scale cohort studies for long-term safety; ③ Metabolism phenotype-based personalized dosing algorithms. These advancements will elevate scyllo-inositol from a “dietary supplement” to a “key tool in preventive medicine for chronic diseases.”
judy@coreychem.com
